>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Verteporfin 维替泊芬; CL 318952

Verteporfin (CL 318952) 是一种用于光动力疗法的光敏剂，用于消除与年龄相关的黄斑变性等疾病相关的眼内异常血管。 Verteporfin 是一种 YAP 抑制剂，可破坏 YAP-TEAD 相互作用。Verteporfin 可以诱导细胞凋亡 (apoptosis)。Verteporfin 是一种自噬 (autophagy) 抑制剂，通过抑制自噬小体形成，在早期阻断自噬。

货号：
TK0498
规格：

1mg

2mg

5mg

10mg

25mg
价格：
￥0.00

产品参数

CAS No.	129497-78-5
生物活性	Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis. Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation.
分子式	C41H42N4O8
分子量	718.79
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	4°C, protect from light
溶解性数据	DMSO : 75 mg/mL (104.34 mM; Need ultrasonic) DMF : 25 mg/mL (34.78 mM; Need ultrasonic)
体内研究	Verteporfin (10 mg/kg, c.s.c.) and BMS-354825 significantly reduces the leukemia cell ratio, and combined therapy further reduced the number of leukemia cells in the spleen.
体外研究	Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI50) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI50 for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 µM, 2.11 µM, and 5.61 µM, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells. Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and NSC 125973 shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T.
文献	•Cancer Cell. 2019 Sep 16;36(3):302-318.e7. •Cell Res. 2020 Mar;30(3):229-243. •Mol Cell. 2019 Jan 3;73(1):7-21.e7. •Hepatology. 2021 Oct;74(4):2133-2153. •Hepatology. 2020 May;71(5):1643-1659. •ACS Nano. 2020 Nov 24;14(11):14907-14918. •Bioact Mater. 2021 Jun 1. •Sci Adv. 2020 May 22;6(21):eaaz5913. •Small. 2020 May 17;e2001837. •EMBO Mol Med. 2018 Nov;10(11). pii: e8699. •Redox Biol. 2020 Oct;37:101745. •Theranostics. 2021 Mar 5;11(11):5197-5213. •Clin Transl Med. 12 September 2021. •J Exp Clin Cancer Res. 2020 Jan 28;39(1):22. •J Exp Clin Cancer Res. 2020 Jan 28;39(1):22. •NPJ Regen Med. 2021 Mar 26;6(1):16. •Oncogene. 2021 Oct 6. •Sci Bull. 2020 Dec 9. •Mol Ther-Nucl Acids. 2021 Feb 26. •Cell Syst. 2018 Apr 25;6(4):424-443.e7. •Cell Death Dis. 2020 Oct 31;11(10):938. •J Pathol. 2021 Jun 22. •Cell Biosci. 2020 Dec 22;10(1):146. •Genes Dis. 19 November 2021. •Stem Cell Res Ther. 2021 Oct 7;12(1):523. •Front Cell Dev Biol. 2021 May 12;9:639111. •Cells. 2022, 11(2), 237. •Cells. 2020 Apr 18;9(4):1010. •Biomed Pharmacother. 2020 Jun;126:110080. •Am J Cancer Res. 2020 Jan 1;10(1):196-210. •J Dent Res. 2019 Jul;98(8):920-929. •J Bone Miner Res. 2021 May 5. •Cancer Cell Int. 2021 Feb 19;21(1):128. •Cancer Cell Int. 2019 Jul 12;19:179. •Front Cell Neurosci. 2018 Dec 11;12:489. •Phytomedicine. 26 December 2021, 153913. •Phytomedicine. 2020, Jul 28. •J Cell Mol Med. 2020 Jul;24(14):8179-8193. •Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165625. •Int Immunopharmacol. 2020 Mar 6;82:106366. •Mediat Inflamm. 28 Jul 2021. •J Cell Biochem. 2020 Mar;121(3):2343-2353. •Mol Immunol. 2019 Mar;107:29-40. •Cancer Manag Res. 2021,13: 4829-4840. •J Pharm Biomed Anal. 20 January 2022, 114473. •Oncol Rep. 2021 Oct;46(4):224. •Oncol Rep. 2021 Jan;45(1):83-94. •Exp Cell Res. 2020 Feb 1;387(1):111745. •Biochem Biophys Res Commun. 2020 Jun 30;527(3):624-630. •Biochem Biophys Res Commun. 2019 May 14;512(4):736-741. •Biochem Biophys Res Commun. 2019 Mar 5;510(2):219-223. •Clin Exp Dermatol. 2021 Oct 8. •Stem Cells Dev. 2020 Oct 15;29(20):1309-1319. •Oncol Lett. August 10, 2021. •Mol Med Rep. 2020 Nov;22(5):3955-3961. •Arch Oral Biol. 2019 Apr;100:23-32. •J Oral Pathol Med. 2020 Apr;49(4):305-310. •Arch Med Res. 2020 Feb;51(2):124-134. •Research Square Preprint. 2021 Sep. •bioRxiv. 2020 May.
纯度及产品资料	≥98%

推荐产品